Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant
• ECOG 0-2
• Women of reproductive age who agree on getting a contraceptive method
• Subjects who fulfill Lugano´s criteria for disease activity
• Subjects who voluntarily accept to participate in this study
Locations
Other Locations
Mexico
Hospital Universitario Dr. José Eleuterio González
RECRUITING
Monterrey
Contact Information
Primary
Perla R Colunga-Pedraza, MD
alrep_rcp@gmail.com
+52 8110761973
Backup
Natalia Huergo-Treviño, MD
nat.hue94@gmail.com
+524442416594
Time Frame
Start Date: 2026-03-17
Estimated Completion Date: 2027-09
Participants
Target number of participants: 10
Treatments
Experimental: Epcoritamab + GemOx
Subjects will receive Gemcitabine/Oxaliplatin at usual doses as well as Epcoritamab with 2 step up doses followed by 12 mg weekly for 3 cycles.
Related Therapeutic Areas
Sponsors
Leads: Hospital Universitario Dr. Jose E. Gonzalez